sirolimus and Pleural-Effusion--Malignant

sirolimus has been researched along with Pleural-Effusion--Malignant* in 3 studies

Other Studies

3 other study(ies) available for sirolimus and Pleural-Effusion--Malignant

ArticleYear
Sirolimus Treatment of an Infant With Intrathoracic Kaposiform Hemangioendothelioma Complicated by Life-threatening Pleural and Pericardial Effusions.
    Journal of pediatric hematology/oncology, 2020, Volume: 42, Issue:1

    Kaposiform hemangioendothelioma (KHE) is a rare infiltrative vascular tumor that may be associated with Kasabach-Merritt Phenomenon (KMP), which is a consumptive coagulopathy with potentially life-threatening thrombocytopenia. Management of KHE and KMP is challenging, and currently, there are no standardized validated treatment protocols. Mammalian target of rapamycin inhibitors have been shown to be effective in the treatment of KHE. We describe a term male who presented as a diagnostic dilemma with life-threatening pleural and pericardial effusions and severe thrombocytopenia. After extensive work-up the etiology for his condition was determined to be KHE with KMP. The patient was commenced on sirolimus and responded well to therapy with resolution of KMP.

    Topics: Hemangioendothelioma; Humans; Infant, Newborn; Kasabach-Merritt Syndrome; Male; Pericardial Effusion; Pleural Effusion, Malignant; Sarcoma, Kaposi; Sirolimus

2020
Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion.
    Respirology (Carlton, Vic.), 2014, Volume: 19, Issue:2

    The impact of temsirolimus was investigated in a murine model of malignant pleural effusion (MPE) created with intrapleural injection of Lewis Lung Cancer (LLC) cells. Temsirolimus (1 or 20 mg/kg) did not affect the pleural fluid volume or the number of pleural tumour foci. In addition, temsirolimus did not affect vascular endothelial growth factor expression by LLC cells in vitro. In conclusion, temsirolimus did not curtail experimental lung-adenocarcinoma-induced MPE.

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Immunosuppressive Agents; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Pleural Effusion, Malignant; Sirolimus; TOR Serine-Threonine Kinases

2014
Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.
    Respiratory investigation, 2013, Volume: 51, Issue:3

    Lymphangioleiomyomatosis (LAM) is a rare disease caused by dysregulated activation of the mammalian target of rapamycin (mTOR). Sirolimus, an inhibitor of mTOR, has been reported to decrease the size of angiomyolipomas and stabilize pulmonary function in patients with LAM. However, the optimal dose for the treatment of LAM remains unclear.. We conducted a retrospective, observational study of 15 patients with LAM who underwent sirolimus therapy for more than 6 months. The efficacy was evaluated by reviewing the patients' clinical courses, pulmonary function and chest radiologic findings before and after the initiation of sirolimus treatment.. All patients had blood trough levels of sirolimus lower than 5ng/mL. Sirolimus treatment improved the annual rates of change in FVC and FEV1 in the 9 patients who were free from chylous effusion (FVC, -101.0 vs. +190.0mL/y, p=0.046 and FEV1, -115.4 vs. +127.8mL/y, p=0.015). The remaining 7 patients had chylous effusion at the start of sirolimus treatment; the chylothorax resolved completely within 1-5 months of treatment in 6 of these cases. These results resembled those of previous studies in which blood trough levels of sirolimus ranged from 5 to 15ng/mL.. Low-dose sirolimus (trough level, 5ng/mL or less) performed as well as the higher doses used previously for improving pulmonary function and decreasing chylous effusion in patients with LAM.

    Topics: Adult; Antibiotics, Antineoplastic; Chylothorax; Female; Forced Expiratory Volume; Humans; Lung Neoplasms; Lymphangiomyoma; Male; Middle Aged; Molecular Targeted Therapy; Pleural Effusion, Malignant; Retrospective Studies; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Vital Capacity

2013